Type 1 interferon activation in SSc: a biomarker, a target or the culprit?

V. Kakkar, S Assassi, Y. Allanore, M. Kuwana, C. Denton, D. Khanna, *F Del Galdo

V. Kakkar, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Department of Rheumatology, Leeds, UK  
S. Assassi, Division of Rheumatology, University of Texas Health Science Center at Houston, TX, USA  
Y. Allanore, M. Kuwana, Department of Allergy and Rheumatology, Nippon Medical School, Tokyo 113-8603, Japan  
C. Denton, D. Khanna, University of Michigan Scleroderma Program, Ann Arbor, MI 48105  
*F Del Galdo, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Department of Rheumatology, Leeds, UK  
f.delgaldo@leeds.ac.uk

* Corresponding author

Abstract

**Purpose of this review:** Systemic sclerosis (SSc) is an autoimmune disease with a high disease burden and mortality rate, within a wide disease heterogeneity across patients. The activation of the type 1 interferon (IFN) pathway has been implicated in the pathogenesis of SSc by a growing number of studies, most of which share several key findings with similar studies in systemic lupus erythematosus. Notably, inhibition of the IFN-α receptor has been recently proven to be effective in active SLE.

An increased expression and activation of type I IFN-regulated genes has been shown to be present in the peripheral blood cells, skin and lungs of a significant proportion of SSc patients. Concordantly, an increased serum concentration of type I IFN inducible proteins is
detectable in a variable proportion of patients with SSc, even at the very early stages of the disease and before onset of clinically detectable damage. Type I IFN activation markers have been found to predict and correlate with response to immunosuppressive treatment as well as severity of organ involvement. A better understanding of the link between Type 1 IFN activation and tissue or vascular fibrosis in SSc pathogenesis has therefore revealed the potential benefit of targeting the interferon-α/β pathway as a future SSc therapeutic option.

**Summary:** The vital role played by type 1 IFN and its regulatory genes in SSc is becoming increasingly evident and strikingly similar to the role observed in SLE. This observation, together with the benefit of type I IFN targeting in SLE, supports the notion of a potential therapeutic benefit in targeting Type I IFN in SSc.

**Keywords:** scleroderma, systemic sclerosis, type 1 interferon, plasmacytoid dendritic cells, CXCL4, Toll-like receptors, interferon regulatory factors

**Introduction**

Systemic sclerosis (SSc) is a progressive, heterogeneous multisystem autoimmune disease, which is characterised by autoimmune activation as well as a pathognomonic tissue and vascular fibrosis.1, 2 It has the greatest mortality amongst the major rheumatic diseases.1, 3, 4 Genetic predisposition combined with triggers activating a persistent immune response at the level of the tissue is thought to drive the pathogenetic process in SSc. Type 1 interferons (T1 IFNs) are a family of cytokines playing a key role in response to viruses and a
variety of danger and damage signals, triggering innate immune activation. The dysregulation in T1 IFN signalling has now been implicated in the pathogenesis of certain autoimmune diseases, including SSc and systemic lupus erythematosus (SLE).(4-6) Clinical evidence of the harmful effects of T1 IFN in SSc, is provided by a randomised, placebo-controlled trial of IFN-α, in patients with early diffuse SSc, where the trial had to be stopped early due to a deleterious effect seen in the lung function of the treatment group, as well as the skin of patients in the placebo group showing greater improvement. The withdrawal and serious adverse events rates were also greater in the treatment group than in the placebo group.(7)

Here we will focus on the evidence for T1 IFN activation in SSc, the potential mechanisms leading to its dysregulation, the predictive role on disease progression and the rationale to target the pathway going forward.

**From Danger Sensors to Interferon Stimulated Genes - A multifaceted defense machinery that can lead to immune mediated tissue damage**

T1 IFNs are a heterogenous family of cytokines, which provide a robust first line of antiviral defence. Type II and III interferon have partially different roles which are outside the scope of this review and have been summarized elsewhere.(8, 9)

T1 IFN can be divided into 5 classes in humans: α, β, ω, ε and κ. All 5, T1 IFN classes signal through the same type 1 IFN heterodimeric receptor complex comprising IFN-α receptor 1 (IFNAR1) and IFNAR2 subunits.
Secretion of T1 IFN in the extracellular space is the terminal event of an “innate” response mechanism to a variety of danger and damage stimuli. The detection of repetitive molecular patterns displayed by a pathogen (pathogen-associated molecular patterns or PAMPs) is one of the stimuli, which is “sensed” by the pattern recognition receptors (PRRs).(10) There are 4 classes of PRRs – the Toll-like receptors (TLRs), the nucleotide-binding oligomerization domain-like receptors (NLR), the retinoic acid inducible gene I (RIG-I) and the C-type lectin receptors.(11) They all differ in ligand recognition, signal transduction and cell localization.

TLRs are the most extensively studied class of PRRs and consist of ten types (TLR 1-10).(10, 12, 13) TLRs are expressed on most nucleated cells, and once they are engaged with their ligand, they lead to T1 IFN pathway activation. While this is true in most cells, Plasmacytoid Dendritic cells (pDCs) are the cells that are “professionally” differentiated to secrete vast amounts of T1 IFN in response to TLR engagement. For this reason, they are believed to play a central part in the T1 IFN mediated immune response and their role has been implicated both in the pathogenesis of SLE (14) and SSc.*(15, 16)

The first indirect evidence of a putative involvement of pDC in the aberrant T1 IFN activation in SSc was suggested by a proteome-wide analysis showing that CXCL4 in the plasma of SSc patients was substantially higher than healthy controls and it predicted presence and worsening of lung fibrosis and pulmonary hypertension. In the same study, the authors implicated pDC as one of the potential sources of CXCL4.(17) More recently, CXCL4 has been found to function as a Damage Associated Molecular Pattern (DAMP) sensor. Lande et al observed that CXCL4 organised microbial and self-DNA into liquid crystalline complexes that amplified TLR9-mediated IFN-α production in pDCs. Importantly,
CXCL4-DNA complexes were present in vivo, and correlated with T1 IFN in SSc blood and skin, revealing a direct link between CXCL4 overexpression and Type 1 IFN production in patients with SSc. *(18) Another study also indicated the infiltration of SSc skin by pDCs, where they were chronically activated, producing high levels of IFN-α and CXCL4. CXCL4 was under the control of phosphatidylinositol 3-kinase δ which was linked to the aberrant presence of TLR8 on pDCs in SSc patients. CXCL4 was also found to potentiate the activities of TLR8 and TLR9 induced IFN production in SSc pDCs. *(16)

Importantly, Ross et al have shown that functional inhibition of pDCs was effective in preventing skin activation and fibrosis in preclinical models of SSc *(15), similar to what has been observed in SLE. *(14)

In another study, anti-CXCL4 antibodies were shown to be present in at least half of SSc patients and correlated with serum/plasma IFN-α levels. Recently, CXCL4 itself was found to behave as a self-antigen, maintaining a vicious cycle by promoting T1 IFN activation via pDCs and anti-CXCL4 antibodies by B cells, sustaining the SSc IFN signature. *(19) Further work with CXCL4 has interestingly shown that the anti-CXCL4 antibodies were present in patients with VEDOSS (Very Early Diagnosis of Systemic Sclerosis), suggesting that this mechanism can intervene very early in the pathogenesis of disease, before clinically apparent tissue damage. *(20)

Activation of TLRs have also been found to play a role in interstitial lung disease (ILD). TLR3 activation by poly I:C has been reported to increase lung inflammatory proteins including the cytokines CCL3, CCL5 and CXCL10, in airway epithelial cells. Importantly, TLR3 knockout (KO) mice showed protection against the inflammatory response. *(21) TLR4 has also been implicated in pulmonary and skin fibrosis, with the ability to activate IRF5. *(22)
Pathogens have long been proposed as a trigger for autoimmune illnesses, and one mechanism for this is ‘molecular mimicry’ between self- and pathogen-derived molecules. Another mechanism, occurs through the inability to clear the pathogen, resulting in infection persistence, and repeated stimulation of the innate immune cells via TLRs.(23, 24) Farina and colleagues have shown evidence of infectious EBV in monocytes triggering SSc. Induction of EBV viral lytic genes resulted in the induction of TLR8 expression in both healthy control and SSc monocytes infected with EBV.(25) Further, Farina et al have shown that EBV can infect endothelial cells and fibroblasts in SSc skin, leading to an aberrant TLR activation.(26) A novel mechanism has also now been demonstrated by which human monocytes bound to EBV recombinant virus are capable to transfer EBV to the endothelial cells. In the same study EBV lytic antigens in scleroderma dermal vessels were detected, suggesting EBV could target endothelial cells in SSc skin, activating TLR 9 in the process and possibly contributing to the vascular injury seen in SSc.(27)

Beyond classic pathogens, there is increasing evidence for an important role played by mitochondria, in the events driving type I IFN activation and subsequent autoimmunity. It is widely accepted that fragmentation in mitochondrial DNA (mtDNA), can lead to the activation of T1 IFN pathway, through the cGAS (cytosolic cyclic GMP-AMP synthase), a specific cytosolic receptor for free DNA which, in turn, activates the endoplasmic reticulum membrane protein, stimulator of interferon genes (STING). cGAS-STING activation by mtDNA was shown to be positively associated with T1 IFN and IL-6 expression in SSc as well as in SLE.(28, 29) Consistent with these findings, mtDNA has been found to be at increased concentration in SSc plasma, with the ability to function as DAMPs and interact
with PRRs.(30) This is one of the putative mechanisms by which necrotic cells or those under stress have been found to activate TLR 9 and the double-stranded DNA sensor, cGAS. Interestingly, it has been also proposed that mtDNA could be damaged as a consequence of oxidative stress due to high exposure to reactive oxidative species (ROS) produced by the mitochondria itself.(28)

Regardless of the source of its secretion, T1IFN signal through IFNAR1 and IFNAR2, which in turn activate Janus kinases (JAKs) signalling pathway downstream.(4, 8) This consists initially with phosphorylation of pre associated JAK1 and tyrosine kinase 2 (TYK2), which triggers kinase activity of signal transducers and activators of transcription 1 and 2 (STAT1 and 2) via cross-phosphorylation. This leads, in turn, to the recruitment of IFN-regulatory factor 9 (IRF9), a member of the family of transcription factors called IFN Regulatory Factors (IRFs), for their ability to regulate the expression of T1 IFN and its effects on target gene expression. IRF9 together with STAT1 and 2 form a complex known as the IFN-stimulated gene factor 3 (ISGF3). This complex translocates to the nucleus to bind to IFN-stimulated response elements (ISRE) in order to induce a family of genes that for this reason are called interferon stimulated genes – ISGs. (4, 8) A summary of the different pathways and key factors mentioned above leading to T1 IFN activation is shown in Figure 1.

**Genetics and Epigenetics of T1 IFN dysregulation in SSc**

Familial association studies have previously shown that family history appears to be the strongest known risk factor for SSc. It was found that amongst first-degree relatives of SSc patients, the prevalence of the disease was 0.33%, with a relative risk factor of 13 when
compared to the general US population, which had a prevalence of 0.026%. (31) A twin study including 42 twin pairs (24 monozygotic and 18 dizygotic), found that the overall concordance of SSc was only 4.2% (1 out of 24) in monozygotic twins and 5.6% in dizygotic twins. The concordance however of anti-nuclear antibodies (ANAs) was significantly higher in monozygotic twins vs dizygotic twins (90% vs 40%) suggesting that concordance for autoimmunity was much higher than the one for clinical disease phenotype. Consistent with these findings, a study in 4612 first degree relatives of 1071 probands revealed an increased risk for familial autoimmunity among subtypes of SSc, with thyroid diseases and SLE showing the most significant increased prevalence when compared to control families, together with Raynaud’s phenomenon and ILD. (32)

The most frequent form of genetic variation in humans is the single-nucleotide polymorphism (SNP), which influences protein function and is key to personalized medicine. (33) In a recent meta-analysis of Genome Wide Association Studies (Meta-GWAS), which included 26,679 individuals, 27 independent genome-wide associated signals were identified, which included 13 new risk loci, and nearly doubled the number of genome-wide hits previously reported in SSc. (34) This meta-analysis has suggested a variety of IFN signalling loci, including T1 IFN regulatory factors IRF4 (35), IRF5 (36, 37), IRF7 (34, 38) and IRF8. (34, 39, 40) (Figure 1)

Interestingly, apart from SSc, the genes have also shown an association with SLE. (41-44). Tyrosine kinase 2 (TYK2) (45), and STAT4 (34, 46) are genes that have also been linked to SSc genetic susceptibility.

A shared genetic background of autoimmune diseases is clearly seen in GWAS, but additionally a vital role played by environmental factors (air pollution, infection and chemical substances such as silicon etc.) (47), and epigenetic influences in the pathogenesis of SSc has
been suggested. Links to the pathogenesis of SSc have been previously reported for all the major epigenetic alterations, including DNA methylation, (48-50) histone modifications, (51, 52) non-coding small (miRNA), and long (lncRNA) RNA transcripts expression. (53-56) For instance, MiR-618 was found to be significantly overexpressed in SSc pDCs, causing an IRF8 dependent inhibition of pDC differentiation and activation, as well as increased production in IFN-α upon TLR9 stimulation. (57) LncRNAs are a larger class of transcribed RNA molecules, that aren’t translated but regulate gene expression. (58) It has recently been shown that a group of lncRNAs were modulated in a T1 IFN-dependent manner in human monocytes in response to TLR4 activation. (59) Among the lncRNAs, the negative regulator of the IFN response (NRIR) was found significantly upregulated in vivo in SSc monocytes, and affected the expression of the ISGs CXCL10 and CXCL11. Therefore, dysregulation of NRIR in SSc monocytes may play a part in contributing to the aberrant IFN response present in SSc patients. (59)

**Evidence of Increased T1 IFN activation in SSc**

Due to the difficulty of directly measuring type 1 IFN levels from human samples, an ‘interferon signature’ including the levels of expression of the transcript levels of multiple known ISGs has been widely used for this purpose. This method established the presence of increased T1 IFN in SLE, and more recently in other rheumatic diseases. (60) The first reported finding of an IFN signature in SSc dates back to 2006. (61) Since then, it has been shown that an IFN signature in blood is found in a large proportion of SSc patients. (5, 62, 63) It has been also shown that activated monocytes and macrophages can be a potent source of T1 IFN and other profibrotic factors, stimulating the proliferation of fibroblasts and
extracellular matrix accumulation.(64) An IFN signature in monocytes has even been found at the earliest phases of SSc, before overt fibrosis, suggesting of this being an early event in SSc pathogenesis.(10)

A higher IFN signature in SSc whole blood or plasma has been found to correlate with the antibody profiling, where anti-topoisomerase and anti-U1-RNP antibodies were associated with a higher IFN signature.(5, 65) Correlation of this higher IFN signature was also seen in more severe vascular manifestations and lung involvement.(65-68) Organs known to be targeted in SSc such as the skin and lung, have also demonstrated an overexpression of ISGs in SSc patients.(69, 70)

Upregulation of ISGs in the skin of SSc patients was also demonstrated in skin biopsy gene expression studies.(70, 71) A study performing microarrays from lung tissue revealed upregulation of ISGs in addition to TGF-β-regulated genes in SSc patients with ILD, with an increased expression of ISGs, associated with a higher rate of progression in ILD.(69) Interestingly, a recent multiomic comparative analysis of the serum profile, peripheral blood cells and skin ISG expression in SSc patients showed that the serum protein profile correlated more closely with the transcriptome of the skin, than that of the PBMCs. This may be due to a spill over effect from diseased end organs and suggests that IFN inducible chemokine concentration may be a better predictor of tissue IFN activity than PBMC ISG expression levels.(72, 73)

Apart from the trial in IFN-α mentioned in the introduction of this review, case reports have been documented of the development of SSc in individuals treated with T1 IFN for other conditions. Interestingly, Anifrolumab (anti-IFNAR1 monoclonal antibody) in a phase 1 trial
of SSc patients led to the suppression of the IFN signature and TGFβ signalling in SSc skin. (74). Additionally, in a graft-versus-host disease (GVHD) mouse model of SSc, neutralisation of IFNAR1, and consequent normalisation in the overexpression of T1 IFN-inducible genes, led to a marked reduction in the dermal fibrosis. (75) Consistent with these findings, in SSc patients treated with high dose cyclophosphamide followed by rescue autologous Hematopoietic Stem Cell Transplantation, clinical response strongly correlated with normalisation in T1 IFN module by RNAseq of peripheral blood cells. (76)

The close mirroring of disease activity of T1 IFN activation has also been shown in the analysis of the SLS2 trial. Assassi et al have shown that higher serum IFN inducible chemokine score predicted a better clinical response in both the cyclophosphamide and the mycophenolate mofetil arms.**(77) Importantly during the second year of the study, higher serum IFN score predicted worse clinical course in patients put on placebo, supporting the notion that IFN activation in SSc is deleterious, unless immunosuppressive treatment is initiated.

Vascular injury plays an important role in organ dysfunction in SSc, and it is the main driver of disease in patients with the limited cutaneous subset (LcSSc) of SSc. T1 IFN has been implicated in the dysregulation of the vascular remodelling process in SSc. Myxovirus-resistance protein A (MxA) which is induced by T1 IFN, was found to correlate with digital ulcerations and lower pulmonary forced vital capacity in SSc. (78) T1 IFN has also been shown to contribute to the increased vascular permeability in SSc through downregulation of Fli1 (friend leukemia integration 1 transcription factor) and vascular endothelial cadherin (VE-cadherin) in endothelial cells and fibroblasts. (79) Features of SSc vasculopathy
were also seen in mice with conditional deletion of Flil in endothelial cells confirming that
t1 IFN-mediated downregulation of Flil enhanced the development of SSc.(80)
Consistent with these observations, IFN inducible chemokines were found to predict
progression of patients with LcSSc as far as a multi morbi-mortality score including skin,
lung, vascular and GI progression.(81)
Taken together these observations suggest that T1 IFN is involved in both tissue and vascular
fibrosis in SSc, strongly supporting the rationale for a direct therapeutic approach targeting
the pathway.

Current experience in T1 IFN Targeting for disease modification

Dysregulation in the T1 IFN response has been shown to contribute to the development of
autoimmunity. Although the clinical manifestations vary amongst the different types of
autoimmune diseases, T1 IFN protein or transcript signatures have now been identified in
many of them (SSc, SLE, dermatomyositis and Sjogrens disease).(5, 10, 82-85)

In SLE, up to 80% of patients were shown to have a T1 IFN signature, with around 50%
having chronically elevated T1 IFN levels, detectable in blood.(86, 87) SLE patients with
high T1 IFN activity, also tend to have higher disease activity scores with a greater tendency
to relapse whilst in remission and a lower response rate to placebo medication.(88-90)
Similarly to what has been observed in SSc, deranged pDC activation also occurs in SLE, and
monoclonal antibodies against pDC have recently shown benefit on cutaneous and musculoskeletal lupus. (91-93)

The effectiveness of blocking IFNAR, which plays a critical role in T1 IFN signalling, has now been concretely demonstrated in SLE patients with the monoclonal antibody Anifrolumab. The phase III Tulip-2 trial met its primary end-point, with an improvement in overall disease activity vs placebo,**(94) leading to FDA and EMA approval for treatment in SLE.

The similarities of T1 IFN activation in SSc therefore informs the rationale to block IFNAR in SSc and determine its therapeutic effectiveness.(4) As mentioned above in this review, early phase 1 study of 34 SSc patients, showed that anifrolumab was well-tolerated and showed peak inhibition of the T1 IFN signature in blood.(95) A follow-up mechanistic study showed that treatment with anifrolumab led to reduction of the T1 IFN signature in whole blood and skin biopsy samples, demonstrating the suppressive effects of the anti-IFNAR1 antibody.(74) These findings provide further support for future larger double-blind, placebo controlled trials of Anifrolumab in early SSc.

**Conclusion**

Over the past few years, substantial progress has been made in deconvoluting the immune complexity of SSc, which has led to identify key molecular and cellular components of T1 IFN signalling involved in disease pathogenesis. In spite of the progress made, many unanswered questions in the pathogenesis of SSc remain. The origin and triggers of T1 IFN,
and the interactions played between genetic and environmental factors, leading to dysfunction in the T1 IFN response still remains a grey area. However, newly discovered function of molecules such as CXCL4, start to lead towards a better understanding of the connections between pDCs, the IFN continuum and the fibrotic process. Further studies are also needed to elucidate downstream processes linking the T1 IFN activation to the exaggerated fibrotic response in fibroblasts and other key effector cells implicated in SSc pathogenesis. Specifically, the identification of specific ligands and signalling pathways driving T1 IFN signalling in SSc will need further investigation with in-vivo and in-vitro studies. This will improve our understanding of SSc pathogenesis, and will increase the armamentarium of the therapeutic targets that could be exploited to improve patient outcome.

Key Points

- The activation of T1 IFN has been implicated in the pathogenesis of SSc and SLE, with inhibition of the IFNα receptor being recently shown to be effective in active SLE
- An increased serum concentration of ISGs is detectable in a variable proportion of patients with SSc, even at the very early stages of the disease, before onset of clinically detectable damage
- The origin and triggers of T1 IFN, and how the interactions between genetic and environmental factors, leads to dysfunction in the T1 IFN response remains unclear
- IFN activation markers have been found to predict and correlate with response to immunosuppressive treatment as well as in the severity of organ involvement
Clinical trials of T1 IFN antagonists in carefully selected SSc patients would lead to a better understanding of the role of T1 IFN plays in SSc pathogenesis, potentially improving outcomes in certain SSc patients.

Acknowledgements

1. Acknowledgments – none

2. Financial Support – none

3. Conflicts of interest – S. Assassi has received grants to his institution from Momenta, Janssen, and Boehringer Ingelheim and consultancy fees from Novartis, AstraZeneca, Boehringer Ingelheim, CSL Behring, and Abbvie.

F. Del Galdo has received research support and consultancy fees from Abbvie, AstraZeneca, Boehringer Ingelheim, Capella, Chemomab, Kymab, Janssen, Mitsubishi-Tanabe.

References


Papers of particular interest have been highlighted as:
* of special interest
** of outstanding interest

*15 – This work demonstrated pDCs and their cytokine production as a key cell type in the pathogenesis of SSc
*17 – This work established a direct link between CXCL4 overexpression and the T1 IFN signature in SSc
**77 – This study demonstrates a composite serum IFN-inducible protein score exhibiting a predictive significance in the response to immunosuppression in SSc-ILD

**93 – This study demonstrated the positive effect of blocking T1 IFN in SLE
TLR1/2 → TLR2-6 → TLR5

TLR4

Endosome

CXCL4

TLR3

TLR7/8

TLR9

IFNAR1

IFNAR2

AP1

IRF3

NF-κB

TBK1

TRAF3

TRAF6

MYD88

TRIF

Cytoplasm

Pro-inflammatory cytokines

Increased expression and/or activation in SSC

SNP in SSC

IRF5

IRF7

IRF9

ISGs

ISRE

MyD88

TRIF

Tyk2

Jak1

Stat1

Stat2

Stat1

Stat2

IrF9

ISGF3

T1 IFN

Pro-inflammatory cytokines